ArticleClinical and vaccine immunology : CVI2011
Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine.
Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Meningococcal carriage by age in the African meningitis belt: a systematic review and meta-analysis.Epidemiology and infection · 2019Pooled it
- Pooled it
- Pooled it
- Pharyngeal carriage of Neisseria species in the African meningitis belt.The Journal of infection · 2016Trial
- Household crowding, social mixing patterns and respiratory symptoms in seven countries of the African meningitis belt.PloS one · 2014Trial
- The effect of recombination on the evolution of a population ofGenome research · 2021Article
- The Epidemiology of Meningococcal Disease and Carriage, Genotypic Characteristics and Antibiotic Resistance ofFrontiers in microbiology · 2021Article
- Molecular insights into meningococcal carriage isolates from Burkina Faso 7 years after introduction of a serogroup A meningococcal conjugate vaccine.Microbial genomics · 2020Article
- Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys.The Lancet. Infectious diseases · 2020Article
- Herd Protection against Meningococcal Disease through Vaccination.Microorganisms · 2020Review
- Risk factors for acquisition of meningococcal carriage in the African meningitis belt.Tropical medicine & international health : TM & IH · 2019Article
- Narrative review of methods and findings of recent studies on the carriage of meningococci and other Neisseria species in the African Meningitis Belt.Tropical medicine & international health : TM & IH · 2019Review
- Compartmental models for seasonal hyperendemic bacterial meningitis in the African meningitis belt.Epidemiology and infection · 2018Article
- Vaccination strategies for the prevention of meningococcal disease.Human vaccines & immunotherapeutics · 2018Review
- Meningococcal carriage within households in the African meningitis belt: A longitudinal pilot study.The Journal of infection · 2018Article
- Article
- Development of a PCR algorithm to detect and characterize Neisseria meningitidis carriage isolates in the African meningitis belt.PloS one · 2018Article
- Increase of Neisseria meningitidis W:cc11 invasive disease in Chile has no correlation with carriage in adolescents.PloS one · 2018Article
- Prevalence and epidemiology of meningococcal carriage in Southern Ethiopia prior to implementation of MenAfriVac, a conjugate vaccine.BMC infectious diseases · 2016Article
- Technical Development of a New Meningococcal Conjugate Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
The serogroup A meningococcal conjugate vaccine MenAfriVac has the potential to confer herd immunity by reducing carriage prevalence of epidemic strains. To better understand this phenomenon, we initiated a meningococcal carriage study to determine the baseline carriage rate and serogroup distribution before vaccine introduction in the 1- to 29-year old population in Burkina Faso, the group chosen for the first introduction of the vaccine. A multiple cross-sectional carriage study was conducted in one urban and two rural districts in Burkina Faso in 2009. Every 3 months, oropharyngeal samples were collected from >5,000 randomly selected individuals within a 4-week period. Isolation and identification of the meningococci from 20,326 samples were performed by national laboratories in Burkina Faso. Confirmation and further strain characterization, including genogrouping, multilocus sequence typing, and porA-fetA sequencing, were performed in Norway. The overall carriage prevalence for meningococci was 3.98%; the highest prevalence was among the 15- to 19-year-olds for males and among the 10- to 14-year-olds for females. Serogroup Y dominated (2.28%), followed by serogroups X (0.44%), A (0.39%), and W135 (0.34%). Carriage prevalence was the highest in the rural districts and in the dry season, but serogroup distribution also varied by district. A total of 29 sequence types (STs) and 51 porA-fetA combinations were identified. The dominant clone was serogroup Y, ST-4375, P1.5-1,2-2/F5-8, belonging to the ST-23 complex (47%). All serogroup A isolates were ST-2859 of the ST-5 complex with P1.20,9/F3-1. This study forms a solid basis for evaluating the impact of MenAfriVac introduction on serogroup A carriage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.